Dopamine and cAMP-regulated phosphoprotein 32 kDa controls both striatal long-term depression and long-term potentiation, opposing forms of synaptic plasticity.
Paolo Calabresi(Università Cattolica del Sacro Cuore), Paul Greengard(Rockefeller University)
Cited by 347
Related Papers
Alpha-synuclein in Parkinson’s disease and other synucleinopathies: from overt neurodegeneration back to early synaptic dysfunction
|Cell Death and Disease|2023|710
Dopamine and cAMP-Regulated Phosphoprotein 32 kDa Controls Both Striatal Long-Term Depression and Long-Term Potentiation, Opposing Forms of Synaptic Plasticity
|Journal of Neuroscience|2000|331
Levodopa in Parkinson’s Disease: Current Status and Future Developments
|Current Neuropharmacology|2017|276
Role of p11 in Cellular and Behavioral Effects of 5-HT4 Receptor Stimulation
|Journal of Neuroscience|2009|166
AP-1 controls the p11-dependent antidepressant response
|Molecular Psychiatry|2020|45